Mark Dawson has helped to build a new drug to fight an aggressive form of blood cancer, discovering the basic science of gene expression in acute myeloid leukaemia (AML), developing the drug to block that action, and leading an international clinical trial to test it.
Mark first explored how genes function in leukaemia, then identified molecules that interrupt the key genetic instructions that perpetuate cancer cells. The drug subsequently developed to treat AML is now the subject of more than 50 clinical trials around the world. [Read more…] about Building a blood cancer treatment from the ground up